Novo Nordisk Stock Surges After FDA Approves Wegovy Pill for Weight Loss 
Blue Origin’s New Glenn Achieves Breakthrough Success With First NASA Mission 
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 
Gold and Silver Prices Slide as Dollar Strength and Easing Tensions Weigh on Metals 
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million 
Nasdaq Proposes Fast-Track Rule to Accelerate Index Inclusion for Major New Listings 
GLP-1 Weight Loss Pills Set to Reshape Food and Fast-Food Industry in 2025 
China to Add Eli Lilly’s Mounjaro to National Health Insurance in 2025 
Lost in space: MethaneSat failed just as NZ was to take over mission control – here’s what we need to know now 
Viking Therapeutics Sees Growing Strategic Interest in $150 Billion Weight-Loss Drug Market 
Sanofi Reports Positive Late-Stage Results for Amlitelimab in Eczema Treatment 
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans 
Washington Post Publisher Will Lewis Steps Down After Layoffs 
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies 
Trump Lifts 25% Tariff on Indian Goods in Strategic U.S.–India Trade and Energy Deal 
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised 
U.S.-India Trade Framework Signals Major Shift in Tariffs, Energy, and Supply Chains 
Tokyo Medical and Dental University and the National Center of Neurology and Psychiatry are planning to develop tailored drugs for patients with genetic disorders to find treatment for extremely rare diseases.
The two Japanese medical institutions will search for rare diseases that have the potential to be treated by nucleic acid drugs from a database of around 2,250 patients.
Nucleic acid drugs are an emerging class of therapeutics,
The development will be carried out based on technology that targets the expression of disease-causing proteins in the mutant gene.
Due to the price and challenges with financial viability, pharmaceutical companies are hesitant to develop medications for exceedingly rare disorders.
According to Takanori Yokota, a professor of neurology and neurological science at Tokyo Medical and Dental University, they hope to make effective patient-tailored nucleic acid drugs and find as many people who can be treated.
The Initiative on Rare and Undiagnosed Diseases, a study that examines the DNA of people whose diseases cannot be detected or for which there is no known cure, will be used to pick participants from among the patients registered in it.
The project catalogs approximately 1,700 linked gene sequences and covers a wide spectrum of illnesses, such as neurological, cardiac, and metabolic problems.
In Japan, only one or two family lines are affected by about 70% of the diseases, and many do not have any reliable treatments.
In addition to the causative gene, factors such as age, the severity of symptoms, and the speed at which the disease is progressing will be taken into account when choosing candidate patients.
